Acorda Therapeutics
ACOR
ACOR was delisted on the 11th of April, 2024.
152 hedge funds and large institutions have $1.57B invested in Acorda Therapeutics in 2014 Q1 according to their latest regulatory filings, with 23 funds opening new positions, 45 increasing their positions, 57 reducing their positions, and 32 closing their positions.
47% more call options, than puts
Call options by funds: $2.9M | Put options by funds: $1.97M
34% more capital invested
Capital invested by funds: $1.17B → $1.57B (+$395M)
7% less funds holding
Funds holding: 163 → 152 (-11)
21% less repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 57
28% less first-time investments, than exits
New positions opened: 23 | Existing positions closed: 32
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
+$33.7M |
| 2 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$24.4M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$22.2M |
| 4 |
PC
PointState Capital
New York
|
+$16.8M |
| 5 |
PCM
Penn Capital Management
Philadelphia,
Pennsylvania
|
+$11.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TSW
Thompson Siegel & Walmsley
Richmond,
Virginia
|
-$15.6M |
| 2 |
AG
Artal Group
Luxembourg
|
-$11.8M |
| 3 |
HM
HealthCor Management
New York
|
-$11.7M |
| 4 |
Goldman Sachs
New York
|
-$11.4M |
| 5 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
-$10.2M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TAM
176
Telluride Asset Management
Wayzata,
Minnesota
| – | -$350K | -100 | Closed |
|
177
Nisa Investment Advisors
St. Louis,
Missouri
| – | -$327K | -93 | Closed |
|
|
VKH
178
Virtu KCG Holdings
New York
| – | -$293K | -84 | Closed |
|
179
Zurich Cantonal Bank
Zurich,
Switzerland
| – | -$292K | -83 | Closed |
|
|
SGH
180
Schonfeld Group Holdings
Jericho,
New York
| – | -$282K | -81 | Closed |
|
|
QBFM
181
QS Batterymarch Financial Management
New York
| – | -$208K | -59 | Closed |
|
182
Acadian Asset Management
Boston,
Massachusetts
| – | -$176K | -50 | Closed |
|
|
QT
183
Quantbot Technologies
New York
| – | -$169K | -48 | Closed |
|
184
SG Americas Securities
New York
| – | -$116K | -33 | Closed |
|
185
Credit Agricole
Montrouge Cedex,
France
| – | -$10K | -3 | Closed |
|
186
Envestnet Asset Management
Chicago,
Illinois
| – | -$1K | – | – |
|
ACOR Hedge Fund Activity: Q1 2014 in Review
152 of the 3,462 institutional investors tracked by Wall St. Rank reported a position in Acorda Therapeutics (ACOR) for Q1 2014, worth a combined $1.57B — up 34% from $1.17B a quarter earlier.
Sellers outnumbered buyers: 32 funds closed out of ACOR and 23 opened new positions — a net loss of 9 holders — while 57 trimmed existing stakes and 45 added.
The largest buyer was Baker Bros. Advisors, opening a new position worth an estimated $33.7M. The largest seller was Thompson Siegel & Walmsley, cutting an estimated $15.6M.
- 152 institutional investors held Acorda Therapeutics (ACOR) as of Q1 2014, down from 163 in Q4 2013.
- Funds reported $1.57B of Acorda Therapeutics stock for Q1 2014, up 34% quarter-over-quarter.
- 23 funds opened new Acorda Therapeutics positions in Q1 2014 and 32 closed out, a net change of -9 holders.
- The largest Acorda Therapeutics buyer in Q1 2014 was Baker Bros. Advisors, an estimated $33.7M added.
- The largest Acorda Therapeutics seller in Q1 2014 was Thompson Siegel & Walmsley, an estimated $15.6M sold.
Based on aggregated 13F filings for Q1 2014.